News and Trends 23 Dec 2016 The 8 Biggest Biotech Medical Fails of 2016 in Europe Although 2016 has brought plenty of good news in medical advances, biotech is an industry where failure is part of the game. Here’s a list of medical fails in biotech to learn from this year. Unfortunately, 2016 has not been a good year for pharma, with revenues in the top companies falling, the lowest number […] December 23, 2016 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 22 Dec 2016 BMS Offers €850M for a British Oncolytic Virus better than CAR-T BMS is offering PsiOxus Therapeutics a massive deal to get exclusive rights of an oncolytic virus that could outperform the promising CAR-T therapies. PsiOxus Therapeutics, based in Oxford, develops immuno-oncolytic viruses to treat solid tumors. Its technology attracted a partnership with Bristol-Myers Squibb earlier this year, which is now offering the British biotech an impressive €850M […] December 22, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 22 Dec 2016 The 10 Biggest Clinical Success Stories of 2016 in European Biotech What are the most impressive advances in medical biotechnology this year? From cancer to peanut allergy, here’s a list of the best success stories of 2016. Biotech is becoming a powerful driving force in medicine, providing innovative therapies that could end some of the most severe diseases. To celebrate the advances in the area of […] December 22, 2016 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 21 Dec 2016 Can partnerships between Biotechs and Academia be the Key to Success? We had the opportunity to hear the story behind the successful Evotec by Thomas Hanke, Executive VP, who gave plenty of advice for biotech companies seeking to grow. One of the biggest biotechs in Europe, with over 1,000 employees, Evotec is now transitioning from offering services to other companies to building its own pipeline. Thomas Hanke, Executive […] December 21, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2016 UPDATE: UniQure keeps afloat with a New CEO and More Clinical Data UniQure’s gene therapy for Hemophilia B is performing well in clinical trials, but the company faces many challenges with its current financial situation. Can it manage to make it to the market? UniQure is famous for launching Glybera, the first globally approved gene therapy, which has been a commercial failure. The company is now indefinitely missing […] December 20, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2016 Japanese Invasion in the European Biologicals Manufacturing space The Japanese manufacturer AGC is acquiring CMC Biologics for nearly €500M, its second European purchase this year aimed at entering the profitable biologicals manufacturing space. CMC Biologics is a contract development and manufacturing organization (CDMO) in Copenhagen with over 500 employees that focuses on biologicals using mammalian and microbial hosts. Its services must have impressed […] December 20, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2016 These are our 10 Most Read Biotech Articles of 2016 From the hottest research areas to the most popular city for biotech, which biotech articles have managed to hook our readers the most this year? After an exciting journey of 2 years, Labiotech.eu is now the leading biotech media in Europe, with over 50k monthly readers. To celebrate the end of another amazing year, we wanted […] December 20, 2016 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2016 What Does ‘Anti-Aging Treatment’ Mean in Biotech? Beyond filling in wrinkles with cosmetics, how do you solve a problem like aging? Here’s how biotech is sinking its teeth into the challenge. “Aging is… broadly [defined] as the time-dependent functional decline that affects most living organisms.” Maria Blasco, Hallmarks of Aging. Can we treat aging directly with medicine? “For the past decade, pharma and […] December 20, 2016 - 5 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 19 Dec 2016 How is Biotech responding to Patient Advocacy in Rare Disease? A panel of experts in rare disease discussed some of the latest trends at Labiotech Refresh, focusing on the growing patient involvement and how it is benefiting this field. Rare diseases are attracting biotech and pharma more and more since they are typically less crowded areas with unmet clinical needs. However, the lower numbers of […] December 19, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 19 Dec 2016 Evotec closes the year partnering with Celgene to treat Alzheimer’s Evotec is closing a fantastic financial year with another top-level partnership; Celgene has decided to trust in its iPSC platform to develop drugs for neurodegenerative diseases. Evotec is a successful drug discovery CRO based in Germany that has managed to sign partnerships with some of the biggest names in Biotech. In addition to previous deals with Bayer, Merck, […] December 19, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 19 Dec 2016 Why don’t more Biotech Startups Succeed? Merck might have a Solution Merck is supporting startups with its Emerging Biotech Initiative, which grants winners up to €100K in products and services. As the number of R&D projects started by biotech companies and academic institutions increases, biotech is proving itself to be a vital part of medicine. So what’s holding startups back? Funding trouble is one of the […] December 19, 2016 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 19 Dec 2016 Following Eli Lilly’s Failure, what’s Next in Alzheimer’s Treatments? Hopes for an Alzheimer’s cure took a hit with Eli Lilly’s recent failure, but it’s not over yet. Probiodrug explains the failure and response. Alzheimer’s Disease devastates families and represents one of the largest financial burdens in society. Now the sixth leading cause of death for all age groups, the neurodegenerative disease cost the US […] December 19, 2016 - 7 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email